Call the Office of Patient Recruitment at 800-411-1222 to speak with one of our Information Specialists.
For those who are deaf, hard-of-hearing, or speech impaired, the Federal Relay Service provides free telecommunications relay services (TRS).
Se habla español.
Clinical Research Study for Patients With Hepatocellular Carcinoma
Hepatocellular Carcinoma (HCC) is the fifth most common cancer in the world. Patients with advanced HCC survive an average of 6 to 9 months. Researchers at the National Institutes of Health are testing the use of an immunotherapy medication called durvalumab, with two other chemotherapy medications, doxorubicin-eluting beads and bevacizumab. This clinical research study will investigate if this combination of medications can stop the progression of HCC.
Who Can Participate:
- 18 years of age or older
- Diagnosed with advanced HCC
- Not pregnant or breastfeeding
- Physical exam and medical history
- Imaging, such as CT or MRI scan
- Electrocardiogram (EKG)
- Patients will receive the study medications every 2- 4 weeks
Location: The NIH Clinical Center, America's Research Hospital is located on the Metro red line (Medical Center stop) in Bethesda, Maryland.
For more information:
NIH Clinical Center Office of Patient Recruitment
800-877-8339 TTY / ASCII
Se habla español
Or go online:
Refer to study # 19-C-0094
Department of Health and Human Services
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
NOTE: PDF documents require the free Adobe Reader.
This page last updated on 02/25/2020